ReviewWorld journal of microbiology & biotechnology2026
Recent progress in microbial production of D-aspartate.
Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
D-Aspartate (D-Asp) is a bioactive compound involved in neuroendocrine regulation and reproductive function in animals, including humans, with tissue-protective effects reported in experimental models, and has potential applications as a raw material for pharmaceuticals and functional food ingredients. It is also used as a side-chain precursor for semisynthetic antibiotics. An established industrial process for D-Asp uses enzymatic conversion by immobilized microbial cells with chemically synthesized D,L-Asp as the starting material and is constrained by dependence on chemical feedstock synthesis. Sustainable alternatives have therefore attracted attention: whole-cell bioconversion of exogenously supplied L-Asp has been demonstrated, whereas de novo production from a renewable carbon source has not yet been reported. This mini-review briefly notes the physiological and industrial contexts that motivate microbial production, and then focuses on the functions, biosynthesis, metabolism, and transport of D-Asp in microorganisms. We further discuss the screening of high-D-Asp-producing microorganisms using a high-throughput colorimetric assay based on D-aspartate oxidase, together with the molecular and cultivation characteristics of the strains identified. These studies indicate that racemization mediated by aspartate racemase, precursor supply via L-asparaginase, competing metabolism associated with bifunctional aspartate aminotransferase, and pH control during cultivation influence extracellular D-Asp accumulation; the contribution of membrane transport remains unresolved. Finally, we highlight the identification of D-Asp exporters, metabolic engineering of production strains, and optimization of cultivation processes as key future priorities for establishing a sustainable and reproducible fermentation platform for D-Asp production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.